Sep. 2 at 12:03 PM
Piper Sandler In A Broad Biotech Note Said -- Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events
$XBI $IBB $FBT MNTL ARKG LABU
Piper Sandler added—Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data.
We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A.
We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil.
Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for REDEMPLO in SHTG and ImmunityBio (IBRX) will report Phase III ANKTIVA data in BCG-naive CIS NMIBC.
We look for clinical data readouts from Arvinas (ARVN), CytomX (CTMX), CRISPR (CRSP), Generate Biomedicines (GENB), Monte Rosa (GLUE), Sutro (STRO) and Xencor (XNCR).